Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
19/26/19	NT$77.40	-0.26%	38,814
16/26/16	NT$77.60	+0.52%	71,571
15/26/15	NT$77.20	-0.39%	1,00,049
14/26/14	NT$77.50	-0.39%	94,098
13/26/13	NT$77.80	-2.75%	4,53,083

End-of-day quote Taipei Exchange

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

77.40TWD

Average target price

153.00TWD

Spread / Average Target

+97.67%

Consensus

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Foresee Pharmaceuticals Co., Ltd.

Company calendar

End-of-day quote Taipei Exchange 19/10/2026			5-day change	1st Jan Change
77.40 ^TWD	-0.26%		-1.02%	-3.97%

12/10	Foresee Pharmaceuticals Co., Ltd. and Changchun GeneScience Pharmaceutical Co., Ltd. Receive China NMPA Approval of CAMCEVI 42 Mg for Treatment of Advanced Prostate Cancer	CI
14/08	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	1.22TCr 38Cr 33Cr 31Cr 28Cr 53Cr 3.56TCr 54Cr 371.71Cr 146.17Cr 1.86TCr 140.81Cr 137.86Cr 5.95TCr	P/E 2024	-9.84x	P/E 2025	-14.1x
Enterprise Value	1.19TCr 37Cr 33Cr 30Cr 28Cr 52Cr 3.49TCr 53Cr 364.15Cr 143.2Cr 1.82TCr 137.95Cr 135.06Cr 5.82TCr	EV / Sales 2024	26x	EV / Sales 2025	28.9x
Free-Float	48.64%	Yield 2024 *	-	Yield 2025	-

12/10	Foresee Pharmaceuticals Co., Ltd. and Changchun GeneScience Pharmaceutical Co., Ltd. Receive China NMPA Approval of CAMCEVI 42 Mg for Treatment of Advanced Prostate Cancer	CI
14/08	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
09/07	Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Brian J. Groch to Chief Commercial Officer, Effective July 1, 2026	CI
08/06	Foresee Pharmaceuticals Oral ALDH2 Activator Mirivadelgat Enters Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2A Platform Trial	CI
27/05	Foresee Pharmaceuticals Completes Casppian Phase 3 Study and Confirms Topline Results for FP-001 42 Mg in Central Precocious Puberty	CI
14/05	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
14/03	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
06/03	Foresee Pharmaceuticals Announces Positive ChHMP Opinion Recommending Approval Of CAMCEVI 21 Mg 3-Month Strength In European Union	CI
04/02	Foresee Pharmaceuticals Co., Ltd. Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty	CI
24/12	Foresee Pharmaceuticals Announces Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust Lh Suppression with 6-Month Dosing Interval of Leuprolide Mesylate	CI
13/11	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
29/25/29	Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer	CI
12/25/12	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

12/24/12	Foresee Pharmaceuticals Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectable Products	AQ
02/24/02	Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of CPP	AQ
31/23/31	Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease	AQ
02/23/02	Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	AQ
02/23/02	Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications	AQ

Foresee Pharmaceuticals Co., Ltd. Share Price

Stocks

6576

TW0006576002

Biotechnology & Medical Research

Valuation: Foresee Pharmaceuticals Co., Ltd.

Chart: Foresee Pharmaceuticals Co., Ltd.

Latest news: Foresee Pharmaceuticals Co., Ltd.

Press Releases: Foresee Pharmaceuticals Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Foresee Pharmaceuticals Co., Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 day	-0.26%
1 week	-1.02%
Current month	-2.64%
1 month	-3.73%
3 months	-3.13%
6 months	+1.04%
Current year	-3.97%

1 week	75.9	79.7
1 month	75.9	86
Current year	75.1	88.3
1 year	71.9	93.7
3 years	57.7	107.5
5 years	57.7	141
10 years	35.1	141

Manager	Title	Age	Since
Benjamin Chien CEO	Chief Executive Officer	-	08/02/2013
Yu Hua Li CTO	Chief Tech/Sci/R&D Officer	-	09/07/2015
Max Chan DFI	Director of Finance/CFO	58	07/10/2019

Director	Title	Age	Since
Chang Jen Yan BRD	Director/Board Member	-	10/01/2013
Sheng Lee Yi BRD	Director/Board Member	-	10/01/2013
George Lee BRD	Director/Board Member	75	03/08/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FORESEE PHARMACEUTICALS CO., LTD.	-0.26%	-1.02%	-3.61%	-4.09%	38Cr
WUXI APPTEC CO., LTD.	+1.52%	-7.16%	+51.66%	+67.41%	6.5TCr
LONZA GROUP AG	+1.52%	+6.83%	+10.89%	+79.30%	5.12TCr
ARGENX SE	+0.30%	-0.46%	-0.03%	+61.89%	5.12TCr
IQVIA HOLDINGS INC.	-0.34%	+1.47%	+25.48%	+42.48%	4.39TCr
BEONE MEDICINES AG	+0.54%	+6.08%	+16.67%	+134.26%	4.2TCr
REVOLUTION MEDICINES, INC.	+2.51%	-5.58%	+239.05%	+531.45%	3.81TCr
CELLTRION, INC.	+2.16%	+10.36%	+18.92%	+59.70%	3.32TCr
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+37.09%	+1.80%	2.52TCr
GENMAB A/S	+1.60%	+2.21%	+27.96%	+28.00%	2.25TCr
Average	+0.82%	+0.08%	+42.41%	+100.22%	3.73TCr
Weighted average by Cap.	+0.96%	+0.04%	+45.72%	+112.78%

	2024	2025
Net sales	42Cr 1.29Cr 1.15Cr 1.06Cr 96.75L 1.82Cr 122.18Cr 1.85Cr 13Cr 5.02Cr 64Cr 4.83Cr 4.73Cr 204.14Cr	43Cr 1.33Cr 1.18Cr 1.1Cr 99.66L 1.87Cr 125.85Cr 1.9Cr 13Cr 5.17Cr 66Cr 4.98Cr 4.88Cr 210.27Cr
Net income	-108.11Cr -3.33Cr -2.97Cr -2.75Cr -2.5Cr -4.69Cr -315.47Cr -4.76Cr -33Cr -13Cr -164.88Cr -12Cr -12Cr -527.09Cr	-88Cr -2.72Cr -2.42Cr -2.24Cr -2.04Cr -3.83Cr -257.71Cr -3.89Cr -27Cr -11Cr -134.7Cr -10Cr -9.99Cr -430.59Cr
Net Debt	-110.7Cr -3.41Cr -3.04Cr -2.81Cr -2.56Cr -4.8Cr -323.03Cr -4.88Cr -34Cr -13Cr -168.83Cr -13Cr -13Cr -539.72Cr	-25Cr -76.26L -67.98L -62.97L -57.26L -1.07Cr -72Cr -1.09Cr -7.55Cr -2.97Cr -38Cr -2.86Cr -2.8Cr -120.81Cr